Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study

  title={Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study},
  author={S. Schutters and H. V. van Megen and J. F. van Veen and D. Denys and H. Westenberg},
  journal={International Clinical Psychopharmacology},
  • S. Schutters, H. V. van Megen, +2 authors H. Westenberg
  • Published 2010
  • Psychology, Medicine
  • International Clinical Psychopharmacology
  • This study is aimed at investigating the efficacy and tolerability of mirtazapine in a generalized social anxiety disorder. Sixty patients with generalized social anxiety disorder were randomly allocated to receive mirtazapine (30–45 mg/day) (n=30) or placebo (n=30) for 12 weeks in a double-blind study design. Primary efficacy was assessed by the Liebowitz Social Anxiety Scale (LSAS) and response to treatment was defined as a reduction of 40% on the LSAS and an improvement on the Clinical… CONTINUE READING
    39 Citations

    Topics from this paper

    Off-label use of mirtazapine for anxiety
    • Highly Influenced
    • PDF
    Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis
    • 18
    • Highly Influenced
    The evidence-based pharmacotherapy of social anxiety disorder.
    • 63
    • Highly Influenced
    • PDF
    Pharmacotherapy for social anxiety disorder (SAnD).
    • 25
    Optimal treatment of social phobia: systematic review and meta-analysis
    • 59
    • PDF


    Mirtazapine in social anxiety disorder: a pilot study
    • 26
    Mirtazapine Treatment of Social Phobia in Women: A Randomized, Double-Blind, Placebo-Controlled Study
    • 61
    • Highly Influential
    Optimizing Treatment in Social Phobia: A Review of Treatment Resistance
    • 34
    Assessing impairment in patients with panic disorder: the Sheehan Disability Scale
    • 245
    Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
    • 521
    • PDF
    • M. Hamilton
    • Psychology, Medicine
    • Journal of neurology, neurosurgery, and psychiatry
    • 1960
    • 26,071
    • PDF
    The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission
    • T. de Boer
    • Medicine
    • International clinical psychopharmacology
    • 1995
    • 96
    The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.
    • 16,441
    • Highly Influential
    The Arizona Sexual Experience Scale (ASEX): reliability and validity.
    • 690